GSK to buy oncology-focused biopharmaceutical firm Tesaro for $5.1bn

This article was originally published here

Based in Waltham of Massachusetts, Tesaro is a commercial-stage firm engaged in the development of advanced therapies to treat cancer. As per the terms of the deal, GSK’s

The post GSK to buy oncology-focused biopharmaceutical firm Tesaro for $5.1bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply